Das Flaggschiff-Medikament mit dem derzeit nahezu der gesamte Umsatz erzielt werden kann heißt Ingrezza. Neurocrine Biosciences Inc.
Yc7b88uopsjvkm
Todd Tushla - Vice President Investor Relations.
Neurocrine biosciences inc. Neurocrine Biosciences Aktie im Überblick. 900964 NBIX US64125C1099. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious challenging and under-addressed neurological endocrine and psychiatric disorders.
Prior to joining Neurocrine Biosciences he was a Senior Scientist in the Neuroscience group at the DuPont Pharmaceutical Company from 1990 to 1993. Securities and Exchange Commission reporting information. NASDAQNBIX will post sales of 27951 million for the current quarter according to Zacks.
SEC filings breakout by MarketWatch. Grigoriadis joined Neurocrine Biosciences in 1993 established the pharmacology and drug screening groups and was most recently a Neurocrine Biosciences Fellow and Vice President of Discovery Biology. Realtimekurs Chart Fundamentaldaten sowie aktuelle Nachrichten und Meinungen.
Neurocrine Biosciences NBIX konnte gerade den Big Picture Breakout absolvieren. View real-time stock prices and stock quotes for a full financial overview. Ausführliches Aktienporträt der Neurocrine Biosciences - WKN 900964 ISIN US64125C1099 - bei finanztreffde topaktuell.
Equities analysts forecast that Neurocrine Biosciences Inc. Eleven analysts have provided estimates for Neurocrine Biosciences earnings with the lowest sales estimate coming in. 16 Zeilen Neurocrine Biosciences Inc Q1 adjusted earnings Miss Estimates.
View the NBIX US. Das Unternehmen befasst sich mit der Entwicklung von Therapien für neurologische endokrine und psychiatrische Störungen. Nachrichten zur Aktie Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc a biopharmaceutical company discovers develops and markets pharmaceutical products for the treatment of neurological endocrine and psychiatric-based diseases and disorders in the United States. NBIX Complete Neurocrine Biosciences Inc. Ist ein Unternehmen aus den Branchen Biotechnologie und Pharma aus den USA.
WASHINGTON dpa-AFX - Neurocrine Biosciences Inc NBIX reported earnings for first quarter that dropped from the same period last year. Stock news by MarketWatch. NEUROCRINE BIOSCIENCES AKTIE und aktueller Aktienkurs.
Beschäftigt sich mit der Entdeckung und Entwicklung von Arzneimitteln bei Krankheiten mit unerfülltem medizinischen Bedarf durch seine Forschungs- und Entwicklungsplattform RD die sich auf neurologische und endokrine Krankheiten und Störungen konzentriert. Is focused on the discovery and development of therapeutics for neuropsychiatric neuroinflammatory and neurodegenerative diseases and disorders. Is engaged in discovering and developing pharmaceuticals in diseases with unmet medical needs through its research and development RD platform focused on.
NASDAQNBIX Q1 2021 Earnings Conference Call May 5 2021 430 PM ET Company Participants.
